-
-
-
-
-
-
-
Jazz Pharmaceuticals Announces Second Quarter 2025 Financial Results and Updates 2025 Financial Guidance
-
-
-
-
-
-
-
Jazz Pharmaceuticals (JAZZ) PT Raised to $230 at Truist Following Chimerix Acquisition
-
-
-
-
-
-
-
Jazz Pharmaceuticals Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024
-
-
-
-
-
-
-
TD Cowen Reiterates Buy Rating on Jazz Pharmaceuticals (JAZZ)
-
-
-
-
-
-
-
Jazz Pharmaceuticals (JAZZ) Announces Orphan Drug Exclusivity for Xywav Oral Solution
-
-
-
-
-
-
-
Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution in Idiopathic Hyp
-
-
-
-
-
-
-
Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2019 Financial Results
-
15,418 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

